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a b s t r a c t
Background: Statins and exercise therapy are clinically effective in preventing cardiovascular events in
patients with coronary artery disease (CAD). The aim of this study was to determine the effects of statins
combined with exercise on the renal function of CAD patients.
Methods: We performed a sub-analysis of a clinical trial that determined the 20-week-effects of two
statins (rosuvastatin, n=14; atorvastatin, n=14) combined with regular exercise on renal function, as
assessed by the estimated glomerular ﬁltration rates (eGFRs) of CAD patients.
Results: The combination of statins and exercise therapy increased eGFRs from 61.1±16.6 at baseline
to 65.8±16.8ml/min/per 1.73m2 (p=0.03), increased serum levels of high-molecular-weight (HMW)
adiponectin, increased ubiquinol/low-density lipoprotein cholesterol (LDL-C) ratios, and decreased high
sensitivity C-reactive protein (hs-CRP). Changes inHMW-adiponectin, ubiquinol/LDL-C ratios andhs-CRP
were signiﬁcantly correlated with changes in eGFR (r=0.597, p=0.001; r=0.437, p=0.02; and r=−0.473,
p=0.01, respectively). Treatment-induced increases inHMW-adiponectin independently correlatedwith
the increases in eGFR (ˇ =0.513, p=0.02) in a multivariate analysis. Both atorvastatin and rosuvastatin
combined with regular exercise produced increases in eGFR. The patients treated with rosuvastatin
exhibited signiﬁcant improvements in eGFR.
Conclusion: Statins combined with exercise signiﬁcantly increased eGFR in CAD patients, and these
improvements in renal function were correlated with increases in HMW-adiponectin levels. The
statins–exercise combination treatment may have provided clinical beneﬁts for patients with CAD partly
through the improvement in renal function.
3 Jap© 201
ntroductionPatients with cardiovascular disease (CVD) and renal dysfunc-
ion are at a higher risk of cardiovascular mortality [1]. We have
reviously reported the beneﬁcial effects of aerobic exercise on
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renal function in patients with coronary artery disease (CAD) and
chronic kidney disease (CKD) and mediated through the modiﬁca-
tion of lipid metabolism [2]. Previous studies have reported that
statins are effective in reducing cardiovascular events and improv-
ing renal function in patients with CKD [3,4].
A recent study suggested the possibility that renal func-
tion may be improved via increases in high-molecular weight
(HMW) adiponectin [5]. Several studies have reported that aer-
obic exercise can increase HMW-adiponectin levels [6–8]. In
contrast, it has been reported that a lipophilic statin failed to
increase HMW-adiponectin levels in healthy men [9]. Recently, the
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ombination of statin treatment and exercise was found to sig-
iﬁcantly lower the all-cause mortality of dyslipidemic patients
10]. Statins and exercise are a recommended and effective ther-
py for patients with CAD. We hypothesized that the combination
f statins and regular exercise therapy would be beneﬁcial to the
anagement of renal dysfunction in CAD patients. To test this
ypothesis, we determined the effects of statin therapy (i.e. the
ydrophilic statin rosuvastatin and the lipophilic statin atorvas-
atin) combined with regular exercise on estimated glomerular
ltration rates (eGFRs), and we clariﬁed the relationship between




This was a prospective, open-label randomized trial. The design
f this study (identiﬁcation number UMIN000002799) has been
escribed in detail previously [11]. The protocol of the Possi-
le Role of Statin Treatment on Exercise Training (PRESET) study
as approved by the Institutional Review Board of the Health
nsurance Hitoyoshi General Hospital in Kumamoto, Japan, and
signed consent form was obtained from each patient. Twenty-
ight JapaneseCADpatientswithhistories ofmyocardial infarction,
ngina pectoris, or ≥50% stenosis in at least one major coronary
rtery were divided at random into atorvastatin (n=14) and rosu-
astatin (n=14) groups. The patients in each group performed
eekly in-hospital 30-minute aerobic exercises on bicycles with
rgometers. The exercises were based on anaerobic thresholds
hat were evaluated with cardiopulmonary exercise tests, and the
atients performed the exercises for 20 weeks. An experienced
egistered exercise rehabilitation instructor instructed all patients
egarding theperformanceof 30-minutewalking exercises at home
hat had Borg scale ratings of 12–13. Atorvastatin was adminis-
ered in 10–40mg/day doses, and rosuvastatinwas administered at
oses of 2.5–20mg/day in the absence of any other lipid-lowering
rugswith the goal of lowering low-density lipoprotein cholesterol
LDL-C) levels below100mg/dl based on the guidelines of the Japan
therosclerosis Society [12].
ome exercise instructions
As has been previously described in detail [11], all patients
ere instructed to perform exercises at home under the supervi-
ion of a registered exercise rehabilitation instructor. The patients
aintained personal healthcare logs in which they recorded their
aily blood pressure, body weight, and exercises performed at
ome. Patients who could not accomplish the home exercises
espite the instructor’s advice were reinstructed to perform the
raining.
MW-adiponectin and ubiquinol assays
Venus blood samples were collected in the morning before the
xercise test following an overnight fast. HMW-adiponectin lev-
ls were measured using enzyme-linked immuno sorbent assays
HMW-adiponectin ELISA kit, FUJIREBIO Inc., Tokyo, Japan) at the
apan SRL Laboratory (Tokyo, Japan). As reported previously [11],
fter centrifugationof serumsamples, the serum levels of ubiquinol
ere analyzed by high-performance liquid chromatography at the
apan SRL Laboratory. Statins block the conversion of 3-hydroxy-3-
ethyl-glutaryl-coenzyme A (HMG-CoA) reductase to mevalonic
cids, which results in the suppression of the downstream prod-
cts of mevalonates, such as cholesterol and ubiquinone [13].
biquinol, which is reduced from ubiquinone and shares morediology 64 (2014) 91–97
than 90% of its identity with plasma coenzyme Q10, has a potent
antioxidant effect [14]. To eliminate the inappropriate inﬂuence of
differences in the reductions in cholesterol levels produced by the
two statins, we examined the ubiquinol/LDL-C ratio rather than
the ubiquinol/total cholesterol ratio [15] because several previ-
ous studies have reported the ubiquinol/LDL-C ratio to be the best
marker of atherosclerotic changes [16,17].
Calculation of eGFR
All creatinine measurements pertaining to this study were per-
formed in the same laboratory. The eGFR values were calculated
using the equation recommended by the Japan Society of Nephrol-
ogy [18].
Statistical analyses
The present study is a sub-analysis of the PRESET study. To
determine whether the samples were normally distributed, we
used the Shapiro–Wilk test. Differences in the continuous base-
line characteristics between the two groups were analyzed with
Student’s t-tests or Mann–Whitney U tests, and the 2-test (or
the Fisher’s exact test when n<5) was used for categorical data.
Paired Student’s t-tests or Wilcoxon tests were used to analyze
the effects of the 20-week treatment. Pearson correlation tests
were used to analyze correlations between changes in eGFR and
changes in other parameters. The 95% conﬁdence intervals and
levels of statistical signiﬁcance (i.e. p-values) were calculated.
To determine the independent association between changes in
eGFR and changes inHMW-adiponectin,we adjusted for the effects
of other covariates on renal function with a multivariate regres-
sion analysis with the forced inclusion of the variables of age, sex,
body mass index (BMI), eGFR, use of angiotensin II receptor block-
ers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-I),
ubiquinol/LDL-C ratio, high sensitivity C-reactive protein (hs-CRP),
high-density lipoprotein cholesterol (HDL-C), and systolic blood
pressure. Data are expressed as the mean± the standard deviation
or themedian value, andp<0.05was considered statistically signif-
icant. All statistical analyses were performed using the Statistical




The baseline characteristics of the sample of the PRESET
study have previously been described [11,19]. As mentioned pre-
viously [11], cardiopulmonary function, as measured by peak
oxygen uptake, improved signiﬁcantly in the entire group after the
20-week treatment regimen.
Changes in eGFR
The baseline characteristics of the entire sample, an increased
eGFR group (increased-eGFR: n=15) and a decreased or no change
eGFR group (non-increased-eGFR: n=13), are described in Table 1.
The mean eGFR of the participants who received statins and exer-
cise intervention increased signiﬁcantly (Fig. 1A). Changes in eGFR
did not correlate with changes in systolic blood pressure or peak
oxygen uptake (Table 2).Changes in metabolic parameters and their relationships to eGFR
As is shown in Fig. 1B, the treatment resulted in a signiﬁ-
cant increase in HMW-adiponectin across the entire group of 28
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Table 1
Baseline characteristics.
Increased-eGFR (n=15) Non-increased-eGFR (n=13) p-Value
Rosuvastatin/atorvastatin group, n (%) 8/7 (53/47%) 6/7 (46/54%) 0.71
Age (years) 66±11 69±11 0.38
Male, n (%) 12 (80%) 9 (69%) 0.67
Body mass index (kg/m2) 25.6±3.7 23.4±0.9 0.25
Systolic blood pressure (mmHg) 123±22 128±23 0.52
Diastolic blood pressure (mmHg) 73±9 76±11 0.47
LVEF (%) 58.9±9.7 62.3±4.8 0.27
eGFR (ml/min/per 1.73m2) 54.8±10.9 68.4±19.4 0.03
HMW-adiponectin (g/ml) 4.4 (2.4–7.8) 3.5 (2.0–7.8) 0.59
HDL-C (mg/dl) 45±13 47±15 0.65
Total cholesterol (mg/dl) 199±37 205±34 0.69
LDL-C (mg/dl) 130±37 128±26 0.85
Triglycerides (mg/dl) 121±40 147±51 0.14
Hypertension, n (%) 14 (93%) 11 (85%) 0.58
Diabetes mellitus, n (%) 6 (40%) 8 (62%) 0.26
Dyslipidemia, n (%) 11 (73%) 12 (92%) 0.33
Smoking, n (%) 5 (33%) 3 (23%) 0.69
Myocardial infarction, n (%) 6 (40%) 3 (23%) 0.44
Angina pectoris, n (%) 6 (40%) 8 (62%) 0.26
Multivessel disease, n (%) 6 (40%) 8 (62%) 0.26
Medical therapy
Aspirin, n (%) 15 (100%) 11 (85%) 0.21
ACE-I, n (%) 7 (47%) 3 (23%) 0.25
ARB, n (%) 6 (40%) 8 (62%) 0.26
Calcium channel blockers, n (%) 8 (53%) 6 (46%) 0.71
-blockers, n (%) 1 (7%) 1 (8%) 1.00
































ahe data are presented as the means± the SDs, median values (with the 25–75th pe
CE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocke
MW-adiponectin, high-molecular-weight adiponectin; LDL-C, low-density lipopro
atients. However, the same treatment had no effect on body
ass index (BMI) (24.5±3.0 kg/m2 to 24.3±2.8 kg/m2, p=0.47),
nd there was no signiﬁcant relationship between changes in
MI and changes in HMW-adiponectin (r=−0.187, p=0.34). There
as no signiﬁcant correlation between baseline eGFRs and HMW-
diponectin (r=−0.187, p=0.340). Changes in HMW-adiponectin
cross the entire group were signiﬁcantly correlated with changes
n eGFR (r=0.597, p=0.001). As mentioned previously [19], the
erum levels of HDL-C, LDL-C, total cholesterol, and triglycerides
mproved signiﬁcantly after the treatment across the entire group,
ut fastingbloodglucoseandhemoglobinA1cdidnot change. There
as a borderline signiﬁcant relationship between changes in HDL-
and changes in eGFR (Table 2); however, changes in LDL-C, total
holesterol, total triglycerides, fasting blood glucose, hemoglobin
1c, and systolic blood pressure did not correlate with changes in
GFR (Table 2).
hanges in ubiquinol/LDL-C ratio and hs-CRP
As is shown in Fig. 1C, the ubiquinol/LDL-C ratio increased sig-
iﬁcantly after the treatment. As reported previously [19], the
ombination treatment signiﬁcantly decreased hs-CRP levels; fur-
hermore, changes in eGFR were signiﬁcantly correlated with
hanges in the ubiquinol/LDL-C ratio (r=0.437, p=0.02) andhs-CRP
r=−0.473, p=0.01).
elationship of HMW-adiponectin and eGFR
After adjustments for age, gender, BMI, baseline levels of eGFR,
he use of ARBs and ACE-Is, changes in ubiquinol/LDL-C ratios,
s-CRP, HDL-C, and systolic blood pressure, multivariate regres-
ion analysis showed that changes in HMW-adiponectin were
igniﬁcantly and independently correlated with changes in eGFR
Table 3). To clarify the relationship between elevated HMW-
diponectin levels and renal function,weclassiﬁed thepatients intoile range) or percentages of patients.
R, estimated glomerular ﬁltration rate; HDL-C, high-density lipoprotein cholesterol;
holesterol; LVEF, left ventricular ejection fraction.
two groups based on changes in HMW-adiponectin levels: those
who exhibited changes in HMW-adiponectin that were greater
than the median value (Higher-Change HMWa group: n=14),
and those who exhibited changes in HMW-adiponectin that were
below the median value (Lower-Change HMWa group: n=14). As
described in Supplementary Table 1, there were no signiﬁcant
differences in the baseline characteristics of these groups. As is
shown in Fig. 1D, the eGFRs of the Higher-Change HMWa group
increased signiﬁcantly, and this pattern was not observed in the
Lower-Change HMWa group.
Supplementary material related to this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jjcc.2013.11.018.
Comparative effects of rosuvastatin and atorvastatin
As reported previously [11], eGFRs at baseline were not
signiﬁcantly different between the rosuvastatin group and the
atorvastatin group. There were no signiﬁcant differences in
HMW-adiponectin, ubiquinol/LDL-C ratio or hs-CRP between the
two groups (Table 4) at study entry. The atorvastatin and rosu-
vastatin groups both exhibited increases in eGFRs (Fig. 2A). The
mean eGFR of the participants who received rosuvastatin and
exercise intervention increased signiﬁcantly, and this increase
was not statistically signiﬁcant for the patients who received
atorvastatin (Fig. 2A). HMW-adiponectin levels (Fig. 2B) and
ubiquinol/LDL-C ratios (Fig. 2C) increased signiﬁcantly, and hs-CRP
levels (Fig. 2D) decreased signiﬁcantly in both groups after the
treatment. Changes in eGFR were signiﬁcantly correlated with
changes in HMW-adiponectin in both statin groups (r=0.750,
p=0.002 and r=0.596, p=0.03 for the rosuvastatin and atorvastatin
groups, respectively). Furthermore, changes in eGFRs were signif-
icantly and positively correlated with changes in ubiquinol/LDL-C
ratios (r=0.658, p=0.01) and negatively correlated with changes in
hs-CRP levels in the rosuvastatin group alone (r= -0.600, p=0.02).
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Fig. 1. Effects of combined exercise and statin treatment on renal function. (A) eGFR, (B) HMW-adiponectin and (C) ubiquinol/LDL-C ratios measured before and after the 20-
















cox-and-whisker plots, the lines within the boxes represent the median values, the
nd the upper and lower bars outside the boxes represent the 90th and 10th p
igh-molecular-weight adiponectin; hs-CRP, high-sensitivity C-reactive protein; LD
iscussion
The major ﬁnding of this work is that the combination
f statins (atorvastatin or rosuvastatin) and regular exercise
igniﬁcantly improved renal function and was correlated with an
ncrease in serum HMW-adiponectin levels in patients with CAD.
tatin therapy combined with regular exercise produced beneﬁcial
rotective effects on renal function that were potentially associ-
ted with an enhancement in circulating HMW-adiponectin levels,
ncreased ubiquinol/LDL-C ratios, and decreased hs-CRP levels in
AD patients.
able 2
orrelation between changes in eGFR and other parameters.
r p-Value
Changes in peak oxygen uptake (ml/min/kg) 0.243 0.21
Changes in HDL-C (mg/dl) 0.356 0.06
Changes in LDL-C (mg/dl) −0.073 0.71
Changes in triglycerides (mg/dl) 0.068 0.73
Changes in total cholesterol (mg/dl) 0.039 0.84
Changes in fasting blood glucose (mg/dl) −0.045 0.82
Changes in hemoglobin A1c (%) −0.163 0.41
Changes in systolic blood pressure (mmHg) 0.293 0.13
GFR, estimated glomerular ﬁltration rate; HDL-C, high-density lipoprotein
holesterol; LDL-C, low-density lipoprotein cholesterol.and lower lines of the boxes represent the 25th and 75th percentiles, respectively,
iles, respectively. eGFR, estimated glomerular ﬁltration rate; HMW-adiponectin,
ow-density lipoprotein cholesterol.
Patients with CVD and renal dysfunction are at high risk of
cardiovascular mortality [1]. Although therapies that aim to pre-
vent the worsening of renal function are clinically important in
cardiovascular risk reduction, recent clinical ﬁndings suggest that
few strategies are potentially effective. In patients with CAD, aer-
obic exercise has a beneﬁcial role in secondary prevention that
is mediated by the modulation of various cardiometabolic risk
factors, such as the elevation of HDL-C, the reduction of LDL-C,
and the improvement of cardiopulmonary function [2,20–22]. We
previously reported the beneﬁcial effects of aerobic exercise on
renal function in patients with CAD and renal dysfunction and
also reported that this effect is correlated with improvements in
serum HDL-C levels [2]. The use of statins is an established strat-
egy for reducing cardiovascular risk because of the pleiotropic
effects of statins that result in reduced LDL-C levels and elevated
HDL-C levels in CAD patients [23–27]. Thus, the combination of
exercise and statin treatment may be beneﬁcial to the renal func-
tion of patients with CAD due to modulation of lipid metabolism.
In the present study, we found a borderline signiﬁcant positive
correlation between changes in eGFR and HDL-C. This work clar-
iﬁed that eGFRs increased by +4.7ml/min/per 1.73m2 (percentage
increase =+9.0%) in 75% of the men aged 67±11 years whose ini-
tial mean eGFR was 61.1±16.6ml/min/per 1.73m2. A previous
report revealed that the rate of eGFR decline is 0.36ml/min/per
1.73m2/year in the general over-40 Japanese population and
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Table 3
Multiple regression analysis of changes in eGFR.
Model Regression coefﬁcient (ˇ) 95% CI p-Value
Age (years) −0.541 −1.0 to −0.1 0.03
Gender (male) −0.144 −13.0 to 6.0 0.45
Body mass index (kg/m2) 0.080 −1.3 to 1.8 0.70
Baseline eGFR (ml/min/per 1.73m2) −0.400 −0.5 to 0.0 0.07
ACE-I (yes) 0.164 −8.8 to 16.0 0.55
ARB (yes) 0.113 −9.7 to 14.4 0.68
Changes in HMW-adiponectin (g/ml) 0.513 0.5 to 4.8 0.02
Changes in ubiquinol/LDL-C ratio (nmol/l/mg/dl) 0.274 −1.3 to 3.6 0.34
Changes in hs-CRP (ng/ml) 0.056 0.0 to 0.0 0.77
Changes in HDL-C (mg/dl) −0.096 −0.8 to 0.5 0.70














































Hodel R2 = 0.684.
CE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocke
MW-adiponectin, high-molecular-weight adiponectin; LDL-C, low-density lipopro
.37ml/min/per 1.73m2/year in males aged between 60 and
9 years [28]. This report also clariﬁed that the rate of eGFR decline
n the general Japanese population of men aged between 60 and
9 years with initial eGFRs of 60–69ml/min/per 1.73m2 is over
.3ml/min/per 1.73m2/year [28]. Thus, this small improvement in
GFR exceeded the yearly rate of eGFR decline in this similar popu-
ation. Our study demonstrated that exercise combined with statin
herapy might prevent declines in eGFR that occur over dozens of
ears. Therefore, we believe that these changes may lead to clinical
eneﬁts.
Adiponectin, which is the most abundant adipocytokine,
nhances insulin sensitivity, promotes fatty acid oxidation, and has
n anti-inﬂammatory effect [29]. Adiponectin exists in three forms
n the peripheral blood: a low-molecular weight form; a medium-
olecular weight form; and a high-molecular weight form.
MW-adiponectin possesses more important vascular protective
ffects [30] and better predictive power for insulin resistance
nd metabolic syndrome than total adiponectin [31]. Although
otal adiponectin levels are paradoxically elevated in patients with
enal failure [32], Kawamoto et al. [5] recently reported that high
evels of HMW-adiponectin are associated with risk reduction
n mild renal dysfunction and demonstrated a positive correla-
ion between eGFR and HMW-adiponectin, which indicates the
linical importance of HMW-adiponectin in patients with CKD.
xercise activates the peroxisome proliferator-activated receptor
(PPAR) [33], which is highly expressed in adipose tissue, skele-
al muscle, and the liver, and this activation leads to increases in
MW-adiponectin levels [34]. Therefore, exercise likely increases
MW-adiponectin via the up-regulation of PPAR. Indeed, several
tudies have reported that aerobic exercise increases circulating
MW-adiponectin levels [6–8]. In contrast, Gouni-Berthold et al.
9] reported that the lipophilic statin simvastatin failed to increase
MW-adiponectin. Thus, it seems that statins combinedwith exer-
ise therapy can increase HMW-adiponectin levels, whereas statin
herapy alone might not increase HMW-adiponectin. The elevation
f total adiponectin levels by statins has previously been reported
35,36]. The present study showed that the combination of stains
nd regular exercise signiﬁcantly increased eGFR and was posi-
ively correlated with increased levels of HMW-adiponectin. We
elieve that the efﬁcacy of this combination therapy might be
able 4
haracteristics of the participating patients at baseline according to the type of statin use
Atorvastatin (n=14)
HMW-adiponectin (g/ml) 5.9 (2.2–9.4)
Ubiquinol/LDL-C (nmol/l/mg/dl) 5.9±1.9
hs-CRP (ng/ml) 1430 (141–2935)
he data are presented as the means± the SDs or the median values (with the 25–75th p
MW-adiponectin, high-molecular-weight adiponectin; LDL-C, low-density lipoprotein cR, estimated glomerular ﬁltration rate; HDL-C, high-density lipoprotein cholesterol;
holesterol; hs-CRP, high-sensitivity C-reactive protein.
explained by increases in renal blood ﬂow. Presently, there are no
reports that clarify whether the combination of statins and exer-
cise therapy increases renal blood ﬂow. It will be important for
further clinical studies to elucidate this relationship because there
are currently feweffective strategies for protecting against declines
in renal blood ﬂow.
Our results also revealed a possible beneﬁcial effect of statins
on renal function. Both the atorvastatin and rosuvastatin groups
exhibited signiﬁcant increases in serum HMW-adiponectin lev-
els and ubiquinol/LDL-C ratios and decreases in hs-CRP levels.
Rosuvastatin in combination with regular exercise signiﬁcantly
improved renal function in the present study. Although signif-
icant correlations between improvements in renal function and
elevations in serum HMW-adiponectin levels were observed in
both groups, improvements in renal function were correlated with
reductions inhs-CRP levels andelevations inubiquinol/LDL-C ratios
only in the rosuvastatin group. Aswehave reportedpreviously [11],
in the PRESET study, atorvastatin combinedwith exercise produced
a signiﬁcantly greater decrease in serum ubiquinol levels than
did rosuvastatin combined with exercise, and this difference may
partially be due to rosuvastatin’s negligible effects on the HMG-
CoA–mevalonic acid pathway in peripheral tissues. This difference
in the effects of rosuvastatin and atorvastatin may be due to the
different properties of these two drugs; rosuvastatin is hydrophilic,
whereas atorvastatin is lipophilic in several organs including mus-
cles and adipose tissues [11]. This ﬁnding suggests that both
rosuvastatin and atorvastatin can potentially provide beneﬁcial
protection of renal function by increasing HMW-adiponectin, but
only rosuvastatin also provides protection mediated by its anti-
oxidative and anti-inﬂammatory properties. Further large-scale
clinical trials are required to conﬁrm the beneﬁcial effects of rosu-
vastatin on renal function.
Our study has several limitations. Firstly, this study did not
distinguish between the distinct effects of aerobic exercise and
statin treatments. Therefore, we cannot conﬁrm which interven-
tion was more important for the protective effect of increased
HMW-adiponectin levels on renal function. This issue should be
further examined in future clinical studies. We were also unable to
compare subjects who had been treated with statins prior to the







holesterol; hs-CRP, high-sensitivity C-reactive protein.
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Fig. 2. Comparison of the atorvastatin and rosuvastatin groups. (A) eGFR, (B) HMW-adiponectin, (C) ubiquinol/LDL-C ratios, and (D) hs-CRP measured before and after the 20-























lox-and-whisker plots, the lines within the boxes represent the median values, the
nd the upper and lower bars outside the boxes represent the 90th and 10th p
igh-molecular-weight adiponectin; hs-CRP, high-sensitivity C-reactive protein; LD
he patients in this study had received statin treatment or under-
oneexerciseprogramsat studyentry. Secondly, the study included
nly a small number of patients from a single center. Thirdly, the
tudy included only small numbers of patients with stage 3a and
b CKD (54%). We could not measure urinary albuminuria or pro-
einuria because this study is a sub-analysis, and no urine samples
ere available for analysis. Fourthly, for two patients in the rosu-
astatin group, an ARB was added or the ARB dosage was increased
uring the study. We excluded these two patients and re-analyzed
he eGFRs because we assumed that these changes in medica-
ion might have accounted for the increases in eGFR. The increase
n eGFR remained signiﬁcant (62.4±16.2ml/min/per 1.73m2 to
6.0±15.9ml/min/per 1.73m2, p=0.031) after excluding these
wo subjects. Fifthly, the eGFRs of the increased-eGFR group were
igniﬁcantly lower than those of the non-increased-eGFR group
Table 1). However, the changes in eGFR levels were signiﬁcantly
ssociated with the changes in HMW-adiponectin in the forced
ultivariate regression models that adjusted for baseline levels of
GFR (Table3). Thisﬁnding indicates that thedifference in thebase-
ine levels of eGFRdidnot signiﬁcantly inﬂuenceourprimary result.and lower lines of the boxes represent the 25th and 75th percentiles, respectively,
iles, respectively. eGFR, estimated glomerular ﬁltration rate; HMW-adiponectin,
ow-density lipoprotein cholesterol.
In conclusion, the combination of statins and exercise therapy
was associated with signiﬁcant improvements in the renal func-
tion of patients with CAD, and this effect was partially mediated by
increases in serum HMW-adiponectin levels.
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